Send to

Choose Destination
Lancet. 1995 Jan 7;345(8941):29-30.

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

Author information

CRC Department of Medical Oncology, University of Manchester, Christie Hospital, UK.


We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 after progression on tamoxifen, for a median duration of 18 months with minimum side effects. Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis. ICI 182780 appears to be a promising new agent for treatment of advanced and early breast cancer.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center